VRML - Vermillion, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.40
-0.05 (-3.11%)
As of 10:24AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.45
Open1.45
Bid0.95 x 500
Ask2.12 x 200
Day's Range1.34 - 1.45
52 Week Range1.03 - 2.85
Volume10,409
Avg. Volume81,618
Market Cap83.998M
Beta1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateMay 18, 2017 - May 19, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Trade prices are not sourced from all markets
  • What Is Vermillion Inc’s (NASDAQ:VRML) Share Price Doing?
    Simply Wall St.2 days ago

    What Is Vermillion Inc’s (NASDAQ:VRML) Share Price Doing?

    Vermillion Inc (NASDAQ:VRML), a medical equipment company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • PR Newswire16 days ago

    Vermillion Announces the Grant of Two Ovarian Cancer Diagnostic Patents

    AUSTIN, Texas , Feb. 5, 2018 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ ...

  • PR Newswirelast month

    Vermillion Announces Agreement with BlueCross BlueShield of Illinois

    AUSTIN, Texas , Jan. 18, 2018 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, ...

  • Vermillion, Inc. :VRML-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
    Capital Cube2 months ago

    Vermillion, Inc. :VRML-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

    Categories: Yahoo FinanceGet free summary analysis Vermillion, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 0.70 million, Net Earnings of USD -2.51 million. Gross margins widened from -31.14% to -11.44% compared to the same period last year, operating (EBITDA) margins now -329.18% from -524.08%. Change in operating cash ... Read more (Read more...)

  • Are Vermillion Inc’s (NASDAQ:VRML) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Vermillion Inc’s (NASDAQ:VRML) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Vermillion Inc (NASDAQ:VRML), with a market cap of $115.80M. However, an important fact which most ignore is: how financially healthyRead More...

  • PR Newswire2 months ago

    Vermillion Appoints Bob Beechey to Newly Created CFO Post

    AUSTIN, Texas , Dec. 19, 2017 /PRNewswire/ --  Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced it has appointed Bob Beechey CPA to the ...

  • PR Newswire3 months ago

    Vermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference

    AUSTIN, Texas , Nov. 21, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri , President and Chief ...

  • PR Newswire3 months ago

    ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1

    Under the new fee schedule, the price for OVA1(MIA) (code 81503) is $897.  This is a four-fold increase over the current CMS rate, and this new rate is based on the median of private payer payments submitted to CMS by companies, including ASPiRA Labs, as part of the market-based payment reform mandated through Protecting Access to Medicare Act of 2014 (PAMA).

  • PR Newswire3 months ago

    Vermillion Announces Publication of Foundational Health Economics Study

    AUSTIN, Texas, Nov. 16, 2017 /PRNewswire/ -- Vermillion (VRML) announced today the acceptance and publication of a novel paper, "Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers" in the journal American Health and Drug Benefits. The paper details the base case of a budget impact model that dynamically tracks the effect of OVA1 adoption in lieu of CA125 in the appropriate patient population on overall cost, both at a plan and per member per month (PMPM) level.  Claims data from a total of over 92,000 health plan members, comprising over 48,000 commercially insured members and 44,000 Medicare beneficiaries, were used in the development of the model. Sensitivity analysis revealed potential savings of up to $0.17 PMPM for commercially insured patients and up to $0.05 for Medicare beneficiaries.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMT

    Q3 2017 Vermillion Inc Earnings Call

  • Associated Press3 months ago

    Vermillion reports 3Q loss

    The Austin, Texas-based company said it had a loss of 6 cents per share. The diagnostic and bio-analytical company posted revenue of $699,000 in the period. In the final minutes of trading on Wednesday, ...

  • PR Newswire3 months ago

    Vermillion Reports Third Quarter 2017 Results

    Conference Call at 4:30 p.m. ET Today AUSTIN, Texas , Nov. 8, 2017 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, reported on its financial ...

  • ACCESSWIRE3 months ago

    Vermillion, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Vermillion, Inc. (NASDAQ: VRML ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:30 PM Eastern Time. ...

  • PR Newswire4 months ago

    Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum

    AUSTIN, Texas , Nov. 6, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that Valerie Palmieri , President and Chief ...

  • PR Newswire4 months ago

    ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1

    AUSTIN, Texas, Nov. 1, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (VRML) and the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA), today announced that it has substantially expanded positive policy coverage with the addition of 14 key managed care providers. This positive coverage is a transition from negative policy to positive policy for many of these plans. "ASPiRA Labs has increased positive coverage for OVA1 with 14 providers totaling over 26 million lives," stated Fred Ferrara, Chief Operating Officer of Vermillion, Inc.  "Two policies totaling approximately 3.8 million covered lives are effective as of October 1, 2017, with the remainder being effective January 2018.  This positive policy coverage is the first step to in-network contracts and market adoption.

  • PR Newswire4 months ago

    ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield

    AUSTIN, Texas , Oct. 31, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, ...

  • PR Newswire4 months ago

    ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®

    AUSTIN, Texas , Oct. 27, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into agreements with Joint Venture Hospital Laboratories, LLC ("JVHL"), ...

  • PR Newswire4 months ago

    Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th

    AUSTIN, Texas , Oct. 25, 2017 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its third quarter 2017 ...

  • PR Newswire5 months ago

    ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®

    AUSTIN, Texas , Oct. 2, 2017 /PRNewswire/ -- ASPiRA Labs, a Vermillion company (NASDAQ: VRML), today announced it has entered into an in-network contract agreement with HealthNet Federal Services, effective ...

  • Is It Too Late To Buy Vermillion Inc (VRML)?
    Simply Wall St.5 months ago

    Is It Too Late To Buy Vermillion Inc (VRML)?

    Vermillion Inc (NASDAQ:VRML), a healthcare equipment and services company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on theRead More...

  • Capital Cube5 months ago

    ETFs with exposure to Vermillion, Inc. : September 19, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Vermillion, Inc. Here are 5 ETFs with the largest exposure to VRML-US. Comparing the performance and risk of Vermillion, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire6 months ago

    Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell

    AUSTIN, Texas, Aug. 31, 2017 /PRNewswire/ -- Vermillion, Inc. (VRML) will launch Ovarian Cancer Awareness Month by ringing the opening bell on Friday, September 1, joined by the New York City chapter of the National Ovarian Cancer Coalition. In the U.S. this year, there is estimated to be approximately 22,000 cases of ovarian cancer and more than 14,000 deaths resulting from this disease. In addition to bringing public awareness to the symptoms, plight, and aiding clinicians in the risk assessment of ovarian cancer, Vermillion has recently achieved a significant milestone as more than 100,000 women have had their ovarian cancer risk assessed with OVA1.